Patients with Crohnʼs Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab

Abstract

This is the first study to show that optimization of IFX is more frequent and faster in obese and overweight patients with CD and occurs within 12 months after beginning IFX, suggesting that an induction regimen with higher doses of IFX and a tight control of IFX concentrations may be needed in these patients.